ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

China drugmaker inks deal to produce Russia's Sputnik V for export

Hualan Biological Engineering expects orders for at least 100 million doses

Hualan said its vaccine unit's deal includes a technology transfer agreement that will provide the necessary capabilities to make the inoculation.   © Reuters

The vaccine arm of Hualan Biological Engineering will be the first Chinese company to produce Russia's promising COVID-19 vaccine, Sputnik V, the company said.

In an announcement issued late Monday, the publicly traded Hualan said its vaccine unit's deal includes a technology transfer agreement that will provide the necessary capabilities to make the inoculation. Once production begins, the Hualan unit expects to receive orders for at least 100 million doses of the viral vector vaccine -- enough to vaccinate 50 million people.

The vaccine has yet to become available in China, which to date has only authorized use of domestically-developed products. A Hualan representative told Caixin that Sputnik V vaccines produced under its new agreement would be manufactured locally and shipped back to Russia.

The deal would make Hualan one of only a handful of Chinese companies to win contracts to produce an overseas-developed vaccine. Fosun Pharmaceutical is one of the only other names to announce a similar deal, under which it will make the COVID-19 vaccine codeveloped by Germany's BioNTech and U.S. drugmaker Pfizer for the Chinese market at an undetermined point in the future, if the vaccine is approved by local regulators.

Hualan's vaccine unit has engaged in its own development of COVID-19 vaccines, but progress has been slow. It is currently developing three types of coronavirus vaccine candidates, including one delivered by nasal spray, but all are in the early stages.

Developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V first received emergency use authorization in Russia in August last year. At that time it had yet to complete Phase 3 testing, usually considered the final and most important leg before a drug's approval, leading many medical professionals to doubt its efficacy. The developer later published interim results in February in the British medical journal The Lancet suggesting the vaccine had an efficacy rate of up to 91.6% and did not cause unexpected side effects.

As of Feb. 12, Sputnik V had been approved for use in 26 countries in Europe, Latin America, the Middle East, Africa, Asia and North America, according to Russia's state-owned Sputnik news agency.

The Russia Direct Investment Fund is handling overseas business for the vaccine, which includes looking for both sales and manufacturing partners. It has signed agreements with 15 companies in 10 countries that will be able to make 1.4 billion doses -- enough to vaccinate 700 million people.

One of the latest countries looking to roll out Sputnik V is India, which is in the midst a major new wave in its outbreak. Last week local drugmaker Dr. Reddy's Laboratories announced it had received permission to import Sputnik for emergency use. On Tuesday Indian media quoted the country's ambassador to Russia as saying the first batch of Sputnik V would be arriving in the country within the next 10 days.

Other media reports cited a senior Dr. Reddy's official saying it could start offering the Sputnik vaccine in the country by late May or early June. India currently has the world's second-highest COVID-19 caseload with 15.3 million confirmed cases, second only to the U.S.

--

Read also the original story.

Caixinglobal.com is the English-language online news portal of Chinese financial and business news media group Caixin. Nikkei agreed with the company to exchange articles in English.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more